A Phase 3 interventional study of Atorvastatin and Ezetimibe in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 19th largest by enrollment of the 97 interventional ones that give a count, is one of 3 that started in 2011, is one of 50 in phase 3, and was the 64th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 406 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 36th largest by enrollment of the 81 interventional ones that give a count, is one of 3 that started in 2011, is one of 58 in phase 3, and was the 76th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether ezetimibe/atorvastatin 10 mg/20 mg combination tablet is equivalent to the coadministration of ezetimibe 10 mg and atorvastatin 20 mg in lowering low-density-lipoprotein-cholesterol (LDL-C) after 6 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 20 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
Drug: Atorvastatin · Drug: Ezetimibe · Drug: Placebo to ezetimibe/atorvastatin
Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/20 mg, placebo to ezetimibe, and placebo to atorvastatin.
Drug: Ezetimibe/atorvastatin · Drug: Placebo to atorvastatin · Drug: Placebo to ezetimibe
20 mg tablet administered orally once daily
Also known as: Lipitor®
10 mg tablet administered orally once daily
Also known as: Zetia®
Drug pages: Ezetimibe · Atorvastatin
Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily
Also known as: Liptruzet®, MK-0653C
Administered orally once daily
Administered orally once daily
Administered orally once daily
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment
Serum LDL-C calculated using Friedewald formula at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
Time frame: Baseline and Week 6
Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment
Serum TC measured at baseline and after 6 week of treatment in each of the 2 treatment periods.
Time frame: Baseline and Week 6
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment
Serum HDL-C calculated at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
Time frame: Baseline and Week 6
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment
Non-HDL-C measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
Time frame: Baseline and Week 6
Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment
Serum Apo B measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
Time frame: Baseline and Week 6
Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment
Serum TG measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
Time frame: Baseline and Week 6
| Milestone | Coadministered/Combination Sequence | Combination/Coadministered Sequence |
|---|---|---|
| Started | 203 | 203 |
| Completed | 187 | 192 |
| Not completed | 16 | 11 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Could not access randomization system | 0 | 1 |
| Milestone | Coadministered/Combination Sequence | Combination/Coadministered Sequence |
|---|---|---|
| Started | 187 | 192 |
| Completed | 181 | 186 |
| Not completed | 6 | 6 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Milestone | Coadministered/Combination Sequence | Combination/Coadministered Sequence |
|---|---|---|
| Started | 181 | 186 |
| Completed | 180 | 184 |
| Not completed | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Serum LDL-C calculated using Friedewald formula at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
| Percentage Change | Ezetimibe/Atorva Fixed Dose Combination | Co-Administration Ezetimibe and Atorvastin |
|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment | -54.0 (-55.8 to -52.2) | -53.8 (-55.7 to -52.0) |
Serum TC measured at baseline and after 6 week of treatment in each of the 2 treatment periods.
| Percentage Change | Ezetimibe/Atorva Fixed Dose Combination | Co-Administration Ezetimibe and Atorvastin |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment | -38.1 (-39.5 to -36.8) | -38.5 (-39.8 to -37.1) |
Serum HDL-C calculated at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
| Percentage Change | Ezetimibe/Atorva Fixed Dose Combination | Co-Administration Ezetimibe and Atorvastin |
|---|---|---|
| Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment | 5.4 (4.0 to 6.7) | 4.6 (3.2 to 5.9) |
Non-HDL-C measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
| Percentage Change | Ezetimibe/Atorva Fixed Dose Combination | Co-Administration Ezetimibe and Atorvastin |
|---|---|---|
| Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment | -50.1 (-51.8 to -48.5) | -50.2 (-51.8 to -48.5) |
Serum Apo B measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
| Percentage Change | Ezetimibe/Atorva Fixed Dose Combination | Co-Administration Ezetimibe and Atorvastin |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment | -42.6 (-44.2 to -41.0) | -43.3 (-44.9 to -41.7) |
Serum TG measured at baseline and after 6 weeks of treatment in each of the 2 treatment periods.
| Percentage Change | Ezetimibe/Atorva Fixed Dose Combination | Co-Administration Ezetimibe and Atorvastin |
|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment | -28.3 (-32.4 to -24.0) | -29.9 (-32.4 to -27.3) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe/Atorva Fixed Dose Combination | — | 2/383 (0.5%) | 0/383 (0%) |
| Co-Administration Ezetimibe and Atorvastin | — | 4/388 (1%) | 0/388 (0%) |
| Event | Ezetimibe/Atorva Fixed Dose Combination | Co-Administration Ezetimibe and Atorvastin |
|---|---|---|
| Myocardial infarctionCardiac disorders | 1/383 | 0/388 |
| HypokalaemiaMetabolism and nutrition disorders | 1/383 | 0/388 |
| Stress cardiomyopathyCardiac disorders | 0/383 | 1/388 |
| Ventricular extrasystolesCardiac disorders | 0/383 | 1/388 |
| Colitis ischaemicGastrointestinal disorders | 0/383 | 1/388 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/383 | 1/388 |
| Age, Customized(Participants) | Coadministered/Combination Sequence | Combination/Coadministered Sequence | Total |
|---|---|---|---|
| 30 to 39 years | 14 | 10 | 24 |
| 40 to 49 years | 35 | 28 | 63 |
| 50 to 59 years | 78 | 81 | 159 |
| 60 to 64 years | 40 | 51 | 91 |
| ≥65 years | 36 | 33 | 69 |
| Sex: Female, Male(Participants) | Coadministered/Combination Sequence | Combination/Coadministered Sequence | Total |
|---|---|---|---|
| Female | 126 | 122 | 248 |
| Male | 77 | 81 | 158 |
No study locations are listed for this record.
The record gives a start of Sep 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Atorvastatin